(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A…
Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and…
(PRESS RELEASE) BASEL, 22-Mar-2021 — /EuropaWire/ — Swiss multinational pharmaceutical Novartis appoints Karen L. Hale as Chief Legal Officer. She…
DUBLIN, 16-Sep-2016 — /EuropaWire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of its Hybrid Closed…
40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) –…
Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast…
Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ —…
Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN…
Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years…
Darmstadt, Germany, 17-7-2014 — /EuropaWire/ — Merck Serono, the biopharmaceutical division of Merck, today announced the appointment of Luciano Rossetti, M.D., as…
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 —…
Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase…